Epidemiology, Pathogenesis And Treatment Of Chronic Lymphocytic Leukaemia: An Update
Keywords:
B-cells, Binet, Bruton tyrosine kinase inhibitors, Chemoimmunotherapy, Chronic Lymphocytic Leukaemia, Immunophenotype, Lymphocytes, RaiAbstract
Chronic lymphocytic leukaemia (CLL) is a neoplastic disease characterised by the accumulation of small, mature-looking lymphocytes in the blood and bone marrow (BM). It is an indolent leukaemia characterised by the progressive accumulation of CD5-positive B cells in the blood and bone marrow because of a failure in programmed cell death or apoptosis. Peripheral blood immunophenotyping is required to confirm CLL diagnosis. The treatment of CLL currently consists of two main approaches — continuous therapy with Bruton's tyrosine kinase inhibitors and fixed-duration regimens combining venetoclax with CD20 antibodies and/or Bruton's tyrosine kinase inhibitors. Chemotherapy and chemo-immunotherapy are gradually becoming obsolete.
References
1. Kipps TJ. Chronic lymphocytic leukemia and related diseases. In: Kaushansky K, Lichtman MA, Kipps TJ, Seligsohn U, Prchal JT, editors. Williams Hematology. 8th ed. New York: McGraw-Hill; 2010. p. 1431-1481.
2. Johnston JB, Seftel MD, Gibson SB. Chronic lymphocytic leukemia. In: Greer JP, Arber DA, Glader B, List AF, Means RT, Paraskevas F, et al., editors. Wintrobe's Clinical Hematology. 13th ed. Philadelphia: Lippincott Williams & Wilkins; 2014. p. 1916-1956.
3. Davids MS, Stilgenbauer S, Tam CS. First-line treatment for CLL in the era of targeted therapy. Blood Cancer J. 2026;16(1):19. doi:10.1038/s41408-025-01434-2.
4. Nwannadi IA, Alao OO, Bazuaye GN, Halim NKD, Omoti CE. The epidemiology of haematological malignancies at the University of Benin Teaching Hospital: a ten-year retrospective study. Int J Epidemiol. 2010;9(2). doi:10.5580/1fbb.
5. Lenartova A, Johannesen TB, Tjønnfjord GE. National trends in incidence and survival of chronic lymphocytic leukemia in Norway for 1953-2012: a systematic analysis of population-based data. Cancer Med. 2016;5(12):3588-3595.
6. Mukkamalla SKR, Taneja A, Malipeddi D, Master RSl. Chronic Lymphocytic Leukemia. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Mar 7; cited 2026 Jun 13. Available
from:
https://www.ncbi.nlm.nih.gov/books/NBK470433/
7. Hallek M. Chronic lymphocytic leukemia: 2025 update on the epidemiology, pathogenesis, diagnosis, and therapy. Am J Hematol. 2025;100(3):450-480. doi:10.1002/ajh.27546.
8. Omoti CE, Nwannadi AI, Obieche JC, Olu-Eddo AN. The epidemiological features of lymphoid malignancies in Benin City, Nigeria: a 15-year study. Pan Afr Med J. 2012;11:17.
9. Scarfò L, Ferreri AJM, Ghia P. Chronic lymphocytic leukaemia. Crit Rev Oncol Hematol. 2016;104:169-182. doi:10.1016/j.critrevonc.2016.06.003.
10. Matsuo K, Suzuki R, Hamajima N, Ogura M, Kagami Y, Taji H, et al. Association between polymorphisms of folate- and methionine-metabolizing enzymes and susceptibility to malignant lymphoma. Blood. 2001;97(10):3205-3209.
11. Gaidano G, Foà R, Dalla-Favera R. Molecular pathogenesis of chronic lymphocytic leukemia. J Clin Invest. 2012;122(10):3432-3438. doi:10.1172/JCI64101.
12. Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med. 2005;352(8):804-815. doi:10.1056/NEJMra041720.
13. Hoffbrand AV. Megaloblastic anaemia. In: Hoffbrand AV, Higgs DR, Keeling DM, Mehta AB, editors. Postgraduate Haematology. 7th ed. Chichester (UK): Wiley-Blackwell; 2015. p. 53-71.
14. Salawu L, Bolarinwa RA, Durosinmi MA. Chronic lymphocytic leukaemia: a twenty-year experience and problems in Ile-Ife, South-Western Nigeria. Afr Health Sci. 2010;10(2):187-192.
15. Niyonizeye E, Wang X, Yan D, et al. Building a new score system for the diagnosis and differential diagnosis of typical CLL/SLL, atypical CLL/SLL, and MCL based on flow cytometry immunophenotyping. Ann Hematol. 2025;104(3):1807-1819. doi:10.1007/s00277-025-06231-2.
16. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111:5446-5456.
17. Tam C, Thompson PA. BTK inhibitors in CLL: second-generation drugs and beyond. Blood Adv. 2024;8(9):2300-2309.
doi:10.1182/bloodadvances.2023012221.
18. Dearden C. Disease-specific complications of chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program. 2008:450-456. doi:10.1182/asheducation-2008.1.450.
19. Oscier D, Dearden C, Erem E, Fegan C, Follows G, Hillmen P, et al. Guidelines on the diagnosis, investigation and management of chronic lymphocytic leukaemia. Br J Haematol. 2012;159:541-564.
20. Jamroziak K, Puła B, Walewski J. Current treatment of chronic lymphocytic leukemia. Curr Treat Options Oncol.
2017;18(1):5. doi:10.1007/s11864-017-0448-2.
21. Al-Sawaf O, Zhang C, Tandon M, et al. Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2020;21(9):1188-1200. doi:10.1016/S1470-2045(20)30443-5.
22. Del Giudice I, Della Starza I, De Falco F, Gaidano G, Sportoletti P. Monitoring response and resistance to treatment in chronic lymphocytic leukemia. Cancers (Basel). 2024;16(11):2049.
doi:10.3390/cancers16112049.
23. Zuber M, Akkala S, Li N, Veettil SK, Tan CJ, Villa Zapata L. Efficacy and effectiveness outcomes of treatments for double-exposed chronic lymphocytic leukemia and small lymphocytic lymphoma patients: a systematic literature review. Cancer Med. 2024;13(18):e70258. doi:10.1002/cam4.70258.
24. Lenartova A, Johannesen TB, Tjønnfjord GE. Chronic lymphocytic leukemia and secondary hematological malignancies: a nationwide cancer registry study. Eur J Haematol. 2020;104:546-553. doi:10.1111/ejh.13396.
25. Woudberg R, Sinanovic E. Cost-effectiveness of tyrosine kinase inhibitor treatment strategies for chronic myeloid leukemia in South Africa. Front Pharmacol. 2025;15:1511603. doi:10.3389/fphar.2024.1511603.
26. Akinola N. Management of CLL in Nigeria: challenges and perspectives. Presented at: ERIC Conference; 2024.
